Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

• ClinicalTrials.gov Identifier: NCT02001051
• Recruitment Status: Terminated
• First Posted: December 4, 2013
• Results First Posted: May 8, 2018
• Last Update Posted: June 14, 2018
• Sponsor: National Cancer Institute (NCI)
• Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Clinical Center Office of the Associates Director for Radiologic&Imaging Sciences
• Information provided by (Responsible Party): Dhaval Patel, M.D., National Institutes of Health Clinical Center (CC)

Study Description

Brief Summary:

Background:

- Adrenal tumors are a common kind of tumor. Some of these secrete extra cortisol into the body, which can lead to diabetes, obesity, and other diseases. Some people with extra cortisol will show symptoms like bruising and muscle weakness. Others will show no signs. This is called subclinical hypercortisolism. Some of these adrenal tumors become malignant. Researchers want to know the best way to treat people with subclinical hypercortisolism. They want to know if removing the tumor by surgery reduces the long-term effects of the disease.

Objectives:

- To see if removing an adrenal tumor by surgery improves blood pressure, diabetes, obesity, osteoporosis, or cholesterol, and cancer detection.

Eligibility:

- Adults 18 and older with an adrenal tumor and high cortisol levels.

Design:

• Participants will be screened with medical history, blood tests, and a computed tomography (CT) scan.
• Participants will have a baseline visit. They will have blood and urine tests and 7 scans. For most scans, a substance is injected through a tube in the arm. Participants will lie still on a table in a machine that takes images.
• Participants will have surgery to remove their tumor. Some will have surgery right away. Some will have surgery 6 months later, after 2 follow-up appointments.
• Participants will have 4 follow-up visits in the first year after surgery. They will have 2 visits the second year, then yearly visits for 3 years. At each follow-up visit, they will have scans and blood tests.

Condition or disease	Intervention/treatment	Phase
Subclinical Hypercortisolism; Cushing Syndrome; Adrenal Neoplasm	Procedure: Adrenalectomy; Other: Observation	Phase 2

Detailed Description:

Background:

• Adrenal incidentalomas are common and found in approximately 4-7% of the population.
• About 0.6 to 25% of patients with an adrenal incidentaloma are found to have subclinical hypercortisolism: 2.3% develop subclinical hypercortisolism during follow up and 0.6% develop clinical hypercortisolism during follow up.
• Subclinical hypercortisolism is defined as biochemical excess of cortisol without signs and symptoms of overt hypercortisolism but may be associated with metabolic complications or disease progression and malignancy.
• Overt signs and symptoms of hypercortisolism include facial plethora, easy bruising, violaceous striae, and proximal muscle weakness.
• Several studies suggest that subclinical hypercortisolism may lead to long term consequences such as diabetes, hypertension, hypercholesterolemia, obesity, and osteoporosis.
• Thus, patients with subclinical hypercortisolism may benefit from operative intervention to halt or reverse metabolic complications associated with the disease and the risk of malignant progression.
• The optimal management of patients with subclinical hypercortisolism and adrenal incidentalomas is controversial and no large randomized trial has been conducted.
• We hypothesize that operative treatment would reduce the risk of long term complications of subclinical hypercortisolism and malignant progression, and propose a prospective randomized trial comparing nonoperative and operative management of subclinical hypercortisolism in patients with an adrenal neoplasm.

Objectives:

Primary Endpoints:

-To determine whether unilateral adrenalectomy in patients diagnosed with subclinical hypercortisolism and adrenal neoplasm results in normalization and/or improvement of hypertension as assessed by reduction in pharmacotherapy and/or normalization of blood pressure (systolic pressure <=140 and diastolic pressure <=90), diabetes as assessed by reduction or elimination of pharmacotherapy and/or improvement in A1C to <6.5%, osteoporosis by increase in bone formation markers indicative of increased bone formation, hypercholesterolemia as assessed by a reduction or elimination of pharmacotherapy and/or reduction in low density lipoprotein (LDL) levels to risk-stratified goal levels as defined by Adult Treatment Panel III (ATP III), and/or overweight or obesity as assessed by a 10 percent reduction in weight at 6 months.

Eligibility:

• An individual with an adrenal neoplasm less than 5 cm in size with biochemically confirmed evidence of hypercortisolism (2 out of 3: dexamethasone suppression test (DST) >3 mcgl/dL, elevated urine free cortisol, and/or morning adrenocorticotrophic hormone (ACTH) <2.2 pmol/l) without overt clinical signs and symptoms.
• Age greater than or equal to 18 years.
• Adults must be able to understand and sign the informed consent document.
• Patients must have laboratory and physical examination parameters within acceptable limits based on standard clinical practice.

Design:

• Prospective randomized study comparing adrenalectomy versus observation.
• Patients assigned to the operative arm will undergo adrenalectomy and then followed postoperatively for normalization and/or improvement of metabolic complications associated with hypercortisolism and histologic examination of the resected tumor.
• Patients assigned to the non-operative arm will be monitored for possible complications associated with hypercortisolism for six months, at which point they will cross-over to the operative intervention arm.
• Patients with bilateral adrenal neoplasms will have the larger adrenal neoplasm used as the primary lesion responsible for subclinical hypercortisolism.
• Demographic, clinical, laboratory and pathologic data will be collected for each patient participant. Data will be securely stored in a computerized database.
• Patients will have biochemical testing to determine if their adrenal neoplasm is functioning or nonfunctioning.
• Projected accrual will be 15 to 20 patients per year for a total of 5 years. Thus, we anticipate accruing 62 patients on this protocol.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 4 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Randomized Control Trial of Adrenalectomy Versus Observation for Subclinical Hypercortisolism
• Actual Study Start Date: November 27, 2013
• Actual Primary Completion Date: August 22, 2017
• Actual Study Completion Date: February 26, 2018

Arms and Interventions

Arm	Intervention/treatment
Operative Arm; operative arm	Procedure: Adrenalectomy; Surgery to remove tumor when enrolled in the protocol.
Delayed Operative Arm; delayed operative arm	Other: Observation; Observation for 6 months prior to surgery

Outcome Measures

Primary Outcome Measures :

1. Proportion of Patients That Have Normalization and/or Improvement of Metabolic Complications After Adrenalectomy [ Time Frame: Assessed at 6 months ]
   Normalization and/or improvement of metabolic complications including hypertension, diabetes, osteoporosis, hypercholesterolemia and/or obesity after adrenalectomy is defined as 35% of patients who improve with surgery versus 5% who do not have surgery.
2. Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) [ Time Frame: Date treatment consent signed to date off study, approximately 39 months and 27 days ]
   Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Secondary Outcome Measures :

1. Proportion of Patients Who Are Found to Have Adrenal Cancer After Adrenalectomy [ Time Frame: Assessed at 6 months ]
   Patients who were tested for and found to have adrenal cancer after adrenalectomy.
2. Proportion of Patients Who Were Diagnosed With Subclinical Hypercortisolism by Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) Scan [ Time Frame: Assessed at 6 months ]
   Proportion of patients who were diagnosed with subclinical hypercortisolism by FDG/PET/CT scan.
3. To Determine the Optimal Diagnostic Test for Subclinical Hypercortisolism [ Time Frame: Assessed at 6 months ]
   An assessment of whether 1 mg dexamethasone suppression test, basal adrenocorticotropic hormone (ACTH), midnight salivary cortisol, or urinary free cortisol is the optimal test to diagnose patients with subclinical hypercortisolism.
4. Proportion of Patients That Have Improvement in Quality of Life (QOL) After Adrenalectomy Compared to Medical Therapy [ Time Frame: Assessed at 6 months ]
   QOL questionnaires were provided to participants to assess well being pre and post operatively. Participants take a self-administered questionnaire to assess physical and mental health according to Cushing's Quality of Life Questionnaire. The score has a minimum of 12 and maximum of 60. A higher score indicates an improved quality of life.
5. Proportion of Patients That Developed Deep Venous Thrombosis With Subclinical Hypercortisolism [ Time Frame: Assessed at 6 months ]
   Proportion of patients that developed deep venous thrombosis with subclinical hypercortisolism regardless of whether the participants received adrenalectomy or not.
6. Correlation Between Dermal Thickness and Patients With Subclinical Hypercortisolism [ Time Frame: Assessed at 6 months ]
   A skin biopsy and skin ultrasound were done to measure the dermal layer of skin to look for a decrease in the thickness of skin as compared to normal values reported in the literature as measured in millimeters of thickness. Diagnostic sensitivity and changes in skin thickness were assessed.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 99 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

• INCLUSION CRITERIA:
• An individual with an adrenal neoplasm less than 5 cm in size with biochemically confirmed evidence of hypercortisolism (2 out of 3: dexamethasone suppression test (DST) >3 mcgl/dL, elevated urine free cortisol, and/or morning adrenocorticotropic hormone (ACTH) <2.2 pmol/l) without overt clinical signs and symptoms.
• Age greater than or equal to 18 years.
• Adults must be able to understand and sign the informed consent document.
• Patients must have laboratory and physical examination parameters within acceptable limits by standard of practice.

EXCLUSION CRITERIA:

• Biochemically and/or radiologically confirmed pheochromocytoma, hyperaldosteronism, or adrenocortical carcinoma.
• Nonfunctioning adrenal neoplasm.
• Pre-existing cancers and/or metastatic disease to the adrenal glands.
• Pregnancy and/or lactation.
• Lack of metabolic complications.
• Imaging features worrisome for malignancy (heterogeneous tumor, presence of calcifications, necrosis, >10 Hounsfield units on an unenhanced computed tomography (CT) scan, and delayed washout of contrast).

Contacts and Locations

Locations

United States, Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Cancer Institute (NCI)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Clinical Center Office of the Associates Director for Radiologic&Imaging Sciences

Investigators

• Principal Investigator: Dhaval T Patel, M.D.; National Cancer Institute (NCI)

  Study Documents (Full-Text)

Documents provided by Dhaval Patel, M.D., National Institutes of Health Clinical Center (CC):

Study Protocol, Statistical Analysis Plan, and Informed Consent Form  [PDF] January 13, 2017

More Information

Additional Information:

NIH Clinical Center Detailed Web Page 

Publications:

Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg. 2009 Mar;249(3):388-91. doi: 10.1097/SLA.0b013e31819a47d2.

Reincke M. Subclinical Cushing's syndrome. Endocrinol Metab Clin North Am. 2000 Mar;29(1):43-56. doi: 10.1016/s0889-8529(05)70115-8.

Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011 May;96(5):1223-36. doi: 10.1210/jc.2010-2722. Epub 2011 Mar 2.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Neychev V, Steinberg SM, Yang L, Mehta A, Nilubol N, Keil MF, Nieman L, Stratakis CA, Kebebew E. Long-Term Outcome of Bilateral Laparoscopic Adrenalectomy Measured by Disease-Specific Questionnaire in a Unique Group of Patients with Cushing's Syndrome. Ann Surg Oncol. 2015 Dec;22 Suppl 3(Suppl 3):S699-706. doi: 10.1245/s10434-015-4605-1. Epub 2015 May 13.

• Responsible Party: Dhaval Patel, M.D., Principal Investigator, National Institutes of Health Clinical Center (CC)
• ClinicalTrials.gov Identifier: NCT02001051
• Other Study ID Numbers: 140021; 14-C-0021
• First Posted: December 4, 2013
• Results First Posted: May 8, 2018
• Last Update Posted: June 14, 2018
• Last Verified: May 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Dhaval Patel, M.D., National Institutes of Health Clinical Center (CC):

Diabetes, Hypertension, Hypercholesterolemia, Obesity, and Osteoporosis.; Nonoperative and Operative Management; Adrenal Incidentalomas; Excess of Cortisol

Additional relevant MeSH terms:

Adrenal Gland Neoplasms; Cushing Syndrome; Adrenocortical Hyperfunction; Adrenal Gland Diseases; Endocrine System Diseases; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms